Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (51-60 of 186) with videos related to

Pageof 19
Sort By:
Scientific Reports|January 26, 2017
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 geneEduardo Tormo, Anna Adam-Artigues, Sandra Ballester, et al.
The Oncologist|June 30, 2011
Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancerNaoki Hayashi, Takayuki Iwamoto, Ana M Gonzalez-Angulo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancerJoan Climent, Jesus Perez-Losada, David A Quigley, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 19, 2008
Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain)Jose Alejandro Pérez-Fidalgo, Josefa Miranda, Isabel Chirivella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancerRosana Sáez, Miguel A Molina, Elizabeth E Ramsey, et al.
Scientific Reports|September 28, 2018
Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young womenSara S Oltra, Maria Peña-Chilet, Victoria Vidal-Tomas, et al.
Clinical Epigenetics|February 22, 2019
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patientsBegoña Pineda, Angel Diaz-Lagares, José Alejandro Pérez-Fidalgo, et al.
Current Medicinal Chemistry|December 21, 2016
Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer ModelsPaula Gonzalez-Alonso, Ion Cristobal, Sandra Zazo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancerJosé Baselga, Joan Albanell, Amparo Ruiz, et al.
Virchows Archiv : an International Journal of Pathology|November 8, 2013
High stability of microRNAs in tissue samples of compromised qualityLorena Peiró-Chova, María Peña-Chilet, José Antonio López-Guerrero, et al.
Pageof 19

Showing results (51-60 of 186) with videos related to

Sort By:
Pageof 19
Scientific Reports|January 26, 2017
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 geneEduardo Tormo, Anna Adam-Artigues, Sandra Ballester, et al.
The Oncologist|June 30, 2011
Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancerNaoki Hayashi, Takayuki Iwamoto, Ana M Gonzalez-Angulo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancerJoan Climent, Jesus Perez-Losada, David A Quigley, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 19, 2008
Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain)Jose Alejandro Pérez-Fidalgo, Josefa Miranda, Isabel Chirivella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancerRosana Sáez, Miguel A Molina, Elizabeth E Ramsey, et al.
Scientific Reports|September 28, 2018
Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young womenSara S Oltra, Maria Peña-Chilet, Victoria Vidal-Tomas, et al.
Clinical Epigenetics|February 22, 2019
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patientsBegoña Pineda, Angel Diaz-Lagares, José Alejandro Pérez-Fidalgo, et al.
Current Medicinal Chemistry|December 21, 2016
Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer ModelsPaula Gonzalez-Alonso, Ion Cristobal, Sandra Zazo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancerJosé Baselga, Joan Albanell, Amparo Ruiz, et al.
Virchows Archiv : an International Journal of Pathology|November 8, 2013
High stability of microRNAs in tissue samples of compromised qualityLorena Peiró-Chova, María Peña-Chilet, José Antonio López-Guerrero, et al.
Pageof 19